bioRxiv Science⌕ Search

Biology subjects

New, C.

Publications and source records attributed to New, C..

2 recordsLinked to original sources

Spatial isotope tracing maps compartmentalized nutrient use across the adult fruit fly

Drosophila melanogaster is a powerful model for studying systemic metabolism. Although metabolism is compartmentalized across tissues, prior work in adult Drosophila has mostly measured it in dissected tissues rather than in situ, limiting the spatial information that can be gained. Here, we combine whole-fly mass-spectrometry imaging with stable-isotope tracing and flux modeling to quantify metabolic activities across the adult fruit fly in a spatially resolved manner. Across 68 tracer-fed Oregon-R female flies and 187,709 pixels, we map 81 metabolites onto eight annotated regions, including muscle, fat body, gut, and nervous system. Glucose labeling and fitted relative fluxes indicate higher glycolytic and tricarboxylic acid cycle turnover in thoracic muscle than in abdominal fat body; proline labels the nervous system and eye; glutamine the abdominal reproductive system and gut. Alanine carries glucose-derived carbon through the hemolymph and transfers nitrogen into glutamate. In flies bearing yorkie-driven gut tumors, alanine contribution to malate rises in gut and abdomen, and reducing gut alanine uptake lowers tumor burden. Together, this work establishes a framework for quantitative spatial metabolic analysis, showing compartmentalized nutrient use across the adult fruit fly.

genetics↗

Glutamine antagonist DRP-104 suppresses tumor growth and enhances response to checkpoint blockade in KEAP1 mutant lung cancer

Loss-of-function mutations in KEAP1 frequently occur in lung cancer and are associated with resistance to standard of care treatment, highlighting the need for the development of targeted therapies. We have previously shown that KEAP1 mutant tumors have increased glutamine consumption to support the metabolic rewiring associated with NRF2 activation. Here, using patient-derived xenograft models and antigenic orthotopic lung cancer models, we show that the novel glutamine antagonist DRP-104 impairs the growth of KEAP1 mutant tumors. We find that DRP-104 suppresses KEAP1 mutant tumor growth by inhibiting glutamine-dependent nucleotide synthesis and promoting anti-tumor CD4 and CD8 T cell responses. Using multimodal single-cell sequencing and ex vivo functional assays, we discover that DRP-104 reverses T cell exhaustion and enhances the function of CD4 and CD8 T cells culminating in an improved response to anti-PD1 therapy. Our pre-clinical findings provide compelling evidence that DRP-104, currently in phase 1 clinical trials, offers a promising therapeutic approach for treating patients with KEAP1 mutant lung cancer. Furthermore, we demonstrate that by combining DRP-104 with checkpoint inhibition, we can achieve suppression of tumor intrinsic metabolism and augmentation of anti-tumor T cell responses.

cancer biology↗